Fig. 2.
a Progression-free survival (PFS) in patients treated with non-bortezomib based therapies, without autologous transplantation (blue curve) and patients treated with bortezomib-based regimens and autologous transplantation (green curve). b Overall survival (OS) in patients treated with treatments non- bortezomib based therapies without autologous transplantation (blue curve) and patients treated with bortezomib-based regimens and autologous transplantation (green curve)